Intratendon Delivery of Leukocyte-Poor Platelet-Rich Plasma Improves Healing Compared With Leukocyte-Rich Platelet-Rich Plasma in a Rabbit Achilles Tendinopathy Model

Abstract

Background:

Chronic tendinopathy is a commonly occurring clinical problem that affects both athletes and inactive middle-aged patients. Although some studies have shown that different platelet-rich plasma (PRP) preparations could exert various therapeutic effects in vitro, the role of leukocytes in PRP has not yet been defined under tendinopathy conditions in vivo.

Purpose:

This study compared the effects of the intratendon delivery of leukocyte-poor PRP (Lp-PRP) versus leukocyte-rich PRP (Lr-PRP) in a rabbit chronic tendinopathy model in vivo.

Study Design:

Controlled laboratory study.

Methods:

Four weeks after a local injection of collagenase in the Achilles tendon, the following treatments were randomly administered on the lesions: injections of (1) 200 μL of Lp-PRP (n = 8), (2) 200 μL of Lr-PRP (n = 8), or (3) 200 μL of saline (n = 8). Healing outcomes were assessed at 4 weeks after therapy with magnetic resonance imaging (MRI), cytokine quantification, real-time polymerase chain reaction analysis of gene expression, histology, and transmission electron microscopy (TEM).

Results:

MRI revealed that the Lr-PRP and saline groups displayed higher signal intensities compared with the Lp-PRP group with T2 mapping. Histologically, the Lp-PRP group displayed significantly better general scores compared with the Lr-PRP (P = .001) and saline (P < .001) groups. Additionally, TEM showed that the Lp-PRP group had larger collagen fibril diameters than the Lr-PRP group (P < .001). Enzyme-linked immunosorbent assay showed a significantly lower level of catabolic cytokine IL-6 in the Lp-PRP group compared with the Lr-PRP (P = .001) and saline (P = .021) groups. The Lp-PRP group displayed significantly increased expression of collagen I compared with the saline group (P = .004) but not the Lr-PRP group. Both the Lp-PRP and Lr-PRP groups exhibited significantly lower matrix metalloproteinase (MMP)–1 and MMP-3 expression levels compared with the saline group. However, only the Lp-PRP group displayed significantly higher expression of TIMP-1 than the saline group (P = .024).

Conclusion:

Compared with Lr-PRP, Lp-PRP improves tendon healing and is a preferable option for the clinical treatment of tendinopathy.

Clinical Relevance:

PRP is widely used in the clinical management of chronic tendinopathy. However, the clinical results are ambiguous. It is imperative to understand the influence of leukocytes on PRP-mediated tissue healing in vivo, which could facilitate the better clinical management of chronic tendinopathy. Further studies are needed to translate our findings to the clinical setting.

Keywords

tendinopathy platelet-rich plasma leukocytes

Get full access to this article

View all access options for this article.

References

Alfredson

. Chronic midportion Achilles tendinopathy: an update on research and treatment. Clin Sports Med. 2003;22(4):727-741.

Amable

Carias

Teixeira

. Platelet-rich plasma preparation for regenerative medicine: optimization and quantification of cytokines and growth factors. Stem Cell Res Ther. 2013;4(3):67.

Andia

Rubio-Azpeitia

Maffulli

. Platelet-rich plasma modulates the secretion of inflammatory/angiogenic proteins by inflamed tenocytes. Clin Orthop Relat Res. 2015;473(5):1624-1634.

Andia

Sanchez

Maffulli

. Tendon healing and platelet-rich plasma therapies. Expert Opin Biol Ther. 2010;10(10):1415-1426.

Andres

Murrell

. Treatment of tendinopathy: what works, what does not, and what is on the horizon. Clin Orthop Relat Res. 2008;466(7):1539-1554.

Anitua

Sanchez

Nurden

Orive

Andia

. New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol. 2006;24(5):227-234.

Boswell

Schnabel

Mohammed

Sundman

Minas

Fortier

. Increasing platelet concentrations in leukocyte-reduced platelet-rich plasma decrease collagen gene synthesis in tendons. Am J Sports Med. 2014;42(1):42-49.

Buckley

. Why does chronic inflammation persist: an unexpected role for fibroblasts. Immunol Lett. 2011;138(1):12-14.

Buckley

Pilling

Lord

Akbar

Scheel-Toellner

Salmon

. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol. 2001;22(4):199-204.

10.

Butler

Juncosa

Dressler

. Functional efficacy of tendon repair processes. Annu Rev Biomed Eng. 2004;6:303-329.

11.

Carr

Murphy

Dakin

. Platelet-rich plasma injection with arthroscopic acromioplasty for chronic rotator cuff tendinopathy: a randomized controlled trial. Am J Sports Med. 2015;43(12):2891-2897.

12.

Castillo

Pouliot

Kim

Dragoo

. Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems. Am J Sports Med. 2011;39(2):266-271.

13.

Chen

. Autologous tenocyte therapy for experimental Achilles tendinopathy in a rabbit model. Tissue Eng Part A. 2011;17(15-16):2037-2048.

14.

Coombes

Bisset

Vicenzino

. Efficacy and safety of corticosteroid injections and other injections for management of tendinopathy: a systematic review of randomised controlled trials. Lancet. 2010;376(9754):1751-1767.

15.

Creaney

Hamilton

. Growth factor delivery methods in the management of sports injuries: the state of play. Br J Sports Med. 2008;42(5):314-320.

16.

Cross

Cole

Spatny

. Leukocyte-reduced platelet-rich plasma normalizes matrix metabolism in torn human rotator cuff tendons. Am J Sports Med. 2015;43(12):2898-2906.

17.

Dakin

Martinez

Yapp

. Inflammation activation and resolution in human tendon disease. Sci Transl Med. 2015;7(311):311ra173.

18.

de Jonge

de Vos

Weir

. One-year follow-up of platelet-rich plasma treatment in chronic Achilles tendinopathy: a double-blind randomized placebo-controlled trial. Am J Sports Med. 2011;39(8):1623-1629.

19.

de Vos

Weir

van Schie

. Platelet-rich plasma injection for chronic Achilles tendinopathy: a randomized controlled trial. JAMA. 2010;303(2):144-149.

20.

Diegelmann

Evans

. Wound healing: an overview of acute, fibrotic and delayed healing. Front Biosci. 2004;9:283-289.

21.

Dohan

Rasmusson

Albrektsson

. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol. 2009;27(3):158-167.

22.

Dragoo

Braun

Durham

. Comparison of the acute inflammatory response of two commercial platelet-rich plasma systems in healthy rabbit tendons. Am J Sports Med. 2012;40(6):1274-1281.

23.

Everts

Brown

Hoffmann

. Platelet-rich plasma preparation using three devices: implications for platelet activation and platelet growth factor release. Growth Factors. 2006;24(3):165-171.

24.

Everts

Knape

Weibrich

. Platelet-rich plasma and platelet gel: a review. J Extra Corpor Technol. 2006;38(2):174-187.

25.

Filardo

Kon

Di Matteo

. Platelet-rich plasma injections for the treatment of refractory Achilles tendinopathy: results at 4 years. Blood Transfus. 2014;12(4):533-540.

26.

Frara

Abdelmagid

Tytell

. Growth and repair factors, osteoactivin, matrix metalloproteinase and heat shock protein 72, increase with resolution of inflammation in musculotendinous tissues in a rat model of repetitive grasping. BMC Musculoskelet Disord. 2016;17:34.

27.

Fukawa

Yamaguchi

Watanabe

. Quantitative assessment of tendon healing by using MR T2 mapping in a rabbit Achilles tendon transection model treated with platelet-rich plasma. Radiology. 2015;276(3):748-755.

28.

Gaweda

Tarczynska

Krzyzanowski

. Treatment of Achilles tendinopathy with platelet-rich plasma. Int J Sports Med. 2010;31(8):577-583.

29.

Gonzalez

Lopez

Alvarez

Perez

Carmona

. Autologous leukocyte-reduced platelet-rich plasma therapy for Achilles tendinopathy induced by collagenase in a rabbit model. Sci Rep. 2016;6:19623.

30.

Jarvinen

Kannus

Maffulli

Khan

. Achilles tendon disorders: etiology and epidemiology. Foot Ankle Clin. 2005;10(2):255-266.

31.

Krogh

Fredberg

Stengaard-Pedersen

Christensen

Jensen

Ellingsen

. Treatment of lateral epicondylitis with platelet-rich plasma, glucocorticoid, or saline: a randomized, double-blind, placebo-controlled trial. Am J Sports Med. 2013;41(3):625-635.

32.

Lake

Ansorge

Soslowsky

. Animal models of tendinopathy. Disabil Rehabil. 2008;30(20-22):1530-1541.

33.

Lopez-Vidriero

Goulding

Simon

Sanchez

Johnson

. The use of platelet-rich plasma in arthroscopy and sports medicine: optimizing the healing environment. Arthroscopy. 2010;26(2):269-278.

34.

Maffulli

Sharma

Luscombe

. Achilles tendinopathy: aetiology and management. J R Soc Med. 2004;97(10):472-476.

35.

Maffulli

Via

Oliva

. Chronic Achilles tendon disorders: tendinopathy and chronic rupture. Clin Sports Med. 2015;34(4):607-624.

36.

Maffulli

Wong

Almekinders

. Types and epidemiology of tendinopathy. Clin Sports Med. 2003;22(4):675-692.

37.

Magalon

Bausset

Serratrice

. Characterization and comparison of 5 platelet-rich plasma preparations in a single-donor model. Arthroscopy. 2014;30(5):629-638.

38.

Mazzocca

McCarthy

Chowaniec

. Platelet-rich plasma differs according to preparation method and human variability. J Bone Joint Surg Am. 2012;94(4):308-316.

39.

Mazzocca

McCarthy

Chowaniec

. The positive effects of different platelet-rich plasma methods on human muscle, bone, and tendon cells. Am J Sports Med. 2012;40(8):1742-1749.

40.

McCarrel

Fortier

. Temporal growth factor release from platelet-rich plasma, trehalose lyophilized platelets, and bone marrow aspirate and their effect on tendon and ligament gene expression. J Orthop Res. 2009;27(8):1033-1042.

41.

McCarrel

Minas

Fortier

. Optimization of leukocyte concentration in platelet-rich plasma for the treatment of tendinopathy. J Bone Joint Surg Am. 2012;94(19):e141-e143.

42.

Mishra

Pavelko

. Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. Am J Sports Med. 2006;34(11):1774-1778.

43.

Mishra

Skrepnik

Edwards

. Efficacy of platelet-rich plasma for chronic tennis elbow: a double-blind, prospective, multicenter, randomized controlled trial of 230 patients. Am J Sports Med. 2014;42(2):463-471.

44.

Moojen

Everts

Schure

. Antimicrobial activity of platelet-leukocyte gel against Staphylococcus aureus. J Orthop Res. 2008;26(3):404-410.

45.

Kim

Park

Roh

. Comparison of the cellular composition and cytokine-release kinetics of various platelet-rich plasma preparations. Am J Sports Med. 2015;43(12):3062-3070.

46.

Pifer

Maerz

Baker

Anderson

. Matrix metalloproteinase content and activity in low-platelet, low-leukocyte and high-platelet, high-leukocyte platelet rich plasma (PRP) and the biologic response to PRP by human ligament fibroblasts. Am J Sports Med. 2014;42(5):1211-1218.

47.

Pingel

Starborg

. 3-D ultrastructure and collagen composition of healthy and overloaded human tendon: evidence of tenocyte and matrix buckling. J Anat. 2014;224(5):548-555.

48.

Radice

Yanez

Gutierrez

Rosales

Pinedo

Coda

. Comparison of magnetic resonance imaging findings in anterior cruciate ligament grafts with and without autologous platelet-derived growth factors. Arthroscopy. 2010;26(1):50-57.

49.

Roche

Calder

. Achilles tendinopathy: a review of the current concepts of treatment. Bone Joint J. 2013;95(10):1299-1307.

50.

Sadoghi

Lohberger

Aigner

. Effect of platelet-rich plasma on the biologic activity of the human rotator-cuff fibroblasts: a controlled in vitro study. J Orthop Res. 2013;31(8):1249-1253.

51.

Schepull

Kvist

Norrman

Trinks

Berlin

Aspenberg

. Autologous platelets have no effect on the healing of human Achilles tendon ruptures: a randomized single-blind study. Am J Sports Med. 2011;39(1):38-47.

52.

Smidt

Assendelft

van der Windt

Hay

Buchbinder

Bouter

. Corticosteroid injections for lateral epicondylitis: a systematic review. Pain. 2002;96(1-2):23-40.

53.

Smith

Blieden

Phipps

. Fibroblasts as sentinel cells: synthesis of chemokines and regulation of inflammation. Am J Pathol. 1997;151(2):317-322.

54.

Spang

Tischer

Salzmann

. Platelet concentrate vs. saline in a rat patellar tendon healing model. Knee Surg Sports Traumatol Arthrosc. 2011;19(3):495-502.

55.

Sundman

Cole

Fortier

. Growth factor and catabolic cytokine concentrations are influenced by the cellular composition of platelet-rich plasma. Am J Sports Med. 2011;39(10):2135-2140.

56.

Sundman

Cole

Karas

. The anti-inflammatory and matrix restorative mechanisms of platelet-rich plasma in osteoarthritis. Am J Sports Med. 2014;42(1):35-41.

57.

Thomopoulos

Parks

Rifkin

Derwin

. Mechanisms of tendon injury and repair. J Orthop Res. 2015;33(6):832-839.

58.

Tillander

Franzen

Norlin

. Fibronectin, MMP-1 and histologic changes in rotator cuff disease. J Orthop Res. 2002;20(6):1358-1364.

59.

Wesner

Defreitas

Bredy

. A pilot study evaluating the effectiveness of platelet-rich plasma therapy for treating degenerative tendinopathies: a randomized control trial with synchronous observational cohort. PLoS One. 2016;11(2):e147842.

60.

Yoshida

Murray

. Peripheral blood mononuclear cells enhance the anabolic effects of platelet-rich plasma on anterior cruciate ligament fibroblasts. J Orthop Res. 2013;31(1):29-34.

61.

Zhang

Wang

. The effects of mechanical loading on tendons: an in vivo and in vitro model study. PLoS One. 2013;8(8):e71740.

62.

Zhang

Chen

Chang

. Harmful effects of leukocyte-rich platelet-rich plasma on rabbit tendon stem cells in vitro. Am J Sports Med. 2016;44(8):1941-1951.

63.

Zhang

Cao

Graf

Meekins

Smith

Phipps

. CD40 engagement up-regulates cyclooxygenase-2 expression and prostaglandin E2 production in human lung fibroblasts. J Immunol. 1998;160(3):1053-1057.

64.

Zhou

Zhang

Hogan

Wang

. The differential effects of leukocyte-containing and pure platelet-rich plasma (PRP) on tendon stem/progenitor cells: implications of PRP application for the clinical treatment of tendon injuries. Stem Cell Res Ther. 2015;6:173.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.24 MB